Novartis

QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy

VANCOUVER, June 15 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) today announced that twelve-month primary analysis results from the Novartis sponsored Phase II MONT BLANC study were presented on June 14, 2009 during the 17th Congress of the European Society of Ophthalmology in Ams...

Lifeclinic Supports the Novartis and International Association of Fire Fighters Campaign Against Hypertension

Lifeclinic will be featuring the LC500 Health Station in support of the Novartis and IAFF STOP•DROP•CONTROL high blood pressure awareness and community health outreach campaign at the IAFF 10th Biennial Dominick F. Barbera EMS Conference. Burtonsville, MD (PRW...

Video: Novartis Receives Approval From FDA to Market Prevacid(R) 24HR as First and Only OTC Proton Pump Inhibitor in Original Prescription Formulation

- This approval will provide greater convenience and broader access to an effective treatment option to the 50 million Americans(1) suffering from frequent heartburn - Once-daily, prescription-strength Prevacid(R) 24HR is the first OTC proton pump inhibitor approved for the treatment of freq...

Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration

- Companies Will Work Together to Protect World's Supply of Donated Blood from Infectious Diseases Until 2025 - Partners Anticipate Continued Expansion into New Global Markets and Development of Innovative New Products, Including Next-Generation PANTHER Instrument - Companies Also Plan E...

Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity

PITTSBURGH, Dec. 2 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL ) today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Novartis Pharmaceuticals Corp., Novartis Corp. and Novartis International AG related to Letrozole Tablets, th...

Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation

CORONA, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Novartis Pharmaceuticals Corporation, Novartis Pharma AG, Novartis AG, Novartis International Pharmaceu...

Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers

- Novartis Vaccines, in partnership with Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) and RediClinic, offers Denver residents a convenient opportunity to get vaccinated against influenza to help protect themselves and the many lives they touch - Vaccination clinics...

Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board

The Madras High Court in the southern Indian state of Tamil Nadu has decided to transfer the Novartis AG’s appeal against the rejection of its patent// plea for the anti-cancer drug Glivec to the Intellectual Property Appellate Board. The decision could be considered a temporary setback to th...

Glivec the hot cancer drug from Novartis

Novartis is the world's sixth-largest drugmaker (by sales). Novartis was formed after merger of two Swiss companies, Sandoz Ltd. and Ciba-Geigy."Novartis is emerging as one of the premier powerhouses in the global pharmaceuticals industry," says Richard R. Stover, senior analyst with brokera...

US Court Allows Teva to Deliver Disputed Drug: Novartis

A US court has authorised Israeli generic medicines group Teva to resume deliveries of a blood pressure drug despite a patent lawsuit by Novartis, the Swiss pharmaceutical group said on Tuesday . A US federal court judge in New Jersey rejected on Monday a request from Novartis to stop Teva Pharmace...

More>>

Novartis in Medical Technology

Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership

- Program Focuses on Expanding Pipeline of Drugs For People with Type 1 Diabetes - NEW YORK, Aug. 5 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation said today that it has entered into a novel collaborative research agreement with the Genomics Institute of th...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two oral sessions at ASH - Exjade results at ASH to show benefits for chronically transfused patients by significantly reducing toxic iron that can dama...

Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!'

- Partnership aims to provide convenient access to vaccination - helping keep kids and teachers in school and parents at work - "Let's Fight Flu Together!" initiative supports CDC's new vaccination recommendations which include children six months to 18 years old(1) - Campaign goal is to i...

Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment

Phase III Study to Explore the Effects of Eligen(R) Delivery Technology and Salmon Calcitonin on Vertebral Fractures in Postmenopausal Women CEDAR KNOLLS, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG has finished ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

- Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer - Plenary session to highlight impact of Zometa(R), the leading IV bisphosphonate, on relapse rate of ...

Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor

Multi-Center International Study to Determine the Efficacy of LBH589 in Patients with Relapsed or Refractory Multiple Myeloma NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) today announced its participation in a Phase II study to dete...

Nektar Therapeutics Reports Second Quarter 2009 Financial Results

...ues resulting from the sale of certain of the company's pulmonary assets to novartis which occurred on December 31, 2008. Cash, cash equivalents, and s...ents 221,948 369,337 Transaction costs from novartis pulmonary asset sale (4,440) ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...ly upon the FDA-approved labeling for the products, and not the information discussed in this news release. ZOMETA is a registered trademark of novartis Oncology. *Editors Note: The FDA has provisionally approved the trade name Prolia(TM) for the proposed indications of treatment and prevention ...

FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent

...d Trevor Mundel, MD, Global Head of Development at novartis Pharma AG. "Novartis is committed to supporting th...factors could have on the values attributed to the novartis Group's assets and liabilities as recorded in the ... sheet, and other risks and factors referred to in novartis AG's current Form 20-F on file with the US Securit...

Novartis in Medical Products

Opal Photoactivator™

Description:... the Opal Photoactivator especially for use in photodynamic therapy with verteporfin, a drug produced by CIBA Vision Corporation, the eye care unit of novartis AG. The Opal laser used in conjunction with Visudyne therapy represents an incredible advance in ocular photodynamic therapy (PDT). In this approach, ...
Company:Lumenis Inc.

Novartis in Medical Definition

Personalized medicine

... prophylactic medications or surgery . Herceptin and Gleevec Two products, Herceptin supplied by Genentech and Gleevec supplied by novartis ,are prescribed on the basis of the outcome of a companion theranostic test. Herceptin treats a category of breast cancer in woman and the test helps ...

Novartis in Medical Dictionary

Carcinoid syndrome

...gt;25 mg of 5-HIAA per day. ... Learn about carcinoid syndrome , get support, and find treatment options for coping with this condition. From novartis Pharmaceuticals. Find more information about Carcinoid Syndrome symptoms here. ... Over 90% of people with carcinoid syndrome experience f...

Antihypertensives

...rtensives . High blood pressure contributes to ... Antihypertensive Medications ... Exforge is a new antihypertensive medication produced by novartis pharma. ... main antihypertensive classes (Angiotensin ... Antihypertensives and Sexual life ... ... answer: 4 category: Antihypertensives 1...

Acromegaly

...ed risk of noncancerous (benign) ... Find information about acromegaly including causes, symptoms and treating, and managing the condition. From novartis Pharmaceuticals. Acromegaly ... Acromegaly is a chronic metabolic disorder in which there is too much growth ... Acromegaly occurs in abou...

Novartis in Biological News

Navigating in the ocean of molecules

... for 2-lipoxygenase and the oestrogen receptor alpha," says Steffen Renner, a former researcher at the Max Planck Institute and now an employee of the novartis pharmaceutical concern. 5-lipoxygenase is a target protein in the treatment of inflammation and bladder cancer, while the oestrogen receptor alpha is ...

Swiss Initiative in Systems Biology launches new projects

...hnology (ETH Zurich und EPF Lausanne), as well as from the Universities of Basel, Lausanne, Geneva and Zurich. The Friedrich-Miescher Institute of the novartis Research Foundation is also represented as the only privately financed institution. Eight groups belong simultaneously to one of the above-mentioned u...

Swine flu experts gather at New York Academy of Sciences May 28

....; Kanta Subbarao, NIH Laboratory of Infectious Diseases; John Treanor, University of Rochester School of Medicine and Dentistry; Philip R. Dormitzer, novartis Vaccines; Scott Harper, New York City Department of Health and Mental Hygiene; and James Matthews, Sanofi Pasteur, moderator. ...

CHIs 5th Biomarker World Congress: Signature Event with Cutting-Edge Agenda

...oject Leader, Early Clinical Development Oncology, novartis Pharma AG Geert Kolvenbag, M.D., Ph.D., Glo...D., Global Head, Marker Localization & Assays, novartis Pharma AG Lawrence J. Lesko, Ph.D., F.C.P.,...Mueller, Ph.D., Project Leader, Safety Assessment, novartis Pharma AG Scott D. Patterson, Ph.D., Execut...

Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations

...otional engagement of more than 20 attendees as they listed to seven presentations. Among the participants were representatives from Kraft Foods Inc., novartis Consumer Health Inc., Kimberly-Clark Corp., JD Power & Associates, TNS Company, OTX Research, and Young & Rubicam. Innerscope measured skin co...

Cellular discovery may lead to targeted treatment for rare form of anemia

...i Neb-Gulati of UC; Alessandro Di Cara, PhD of Friedrich Miescher Institute for Biomedical Research in Switzerland; Francois Natt and Jonathan Hall of novartis Institutes for Biomedical Research in Switzerland; Rosa Bernardi MD, PhD, of San Raffaele, Institute Via Olgettina in Italy; and Pier Paolo Pandolfi, ...

The quest for specific anti-inflammatory treatment

...There are very few teams today researching the anti-inflammatory abilities of the C1P molecule one team in Virginia (USA), the pharmaceutical company novartis (Austria) and specific research teams such as that of Antonio Gmez-Muoz, the first to investigate them in 1995. At present, the research is being und...

Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics

...rate hypotheses when trying to unravel the cellular machinery underlying toxicity responses, which then are tested more thoroughly using other assays. novartis is employing known toxic compounds to develop the techniques to understand the mechanistic actions of toxicity. Such screening led to the recent valid...

American Society for Microbiology 108th General Meeting

...the University of Wisconsin presenting on the use of photosynthetic bacteria to harness the power of the sun for renewable energy and Rino Rappuoli of novartis Vaccine and Diagnostics examining pan-genomic approaches to the development of new vaccines and antibiotics. The session will conclude with a keynote...

Academy honors 13 for major contributions to science

...es that, in the broadest sense, contributes to the better understanding of the natural sciences and to the benefit of humanity goes to JOANNE STUBBE, novartis Professor, departments of chemistry and biology, Massachusetts Institute of Technology, Cambridge, "for landmark work on the mechanisms and regulation...

Novartis in Biological Technology

Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD

Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced changes to its global collaboration with Novartis for th...

Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US

Even Among Companies Doing Well, Relationships Weaken in Many Countries NEW YORK, Feb. 17 /PRNewswire/ -- New TNS Healthcare research shows that physicians in four out of the five major European countries -- the UK, Germany, Spain and Italy -- give Novartis top marks for effectively deliverin...

Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million

SAN CARLOS, Calif., Dec. 31 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million in cash. The transaction ...

Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder

SAN CARLOS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- (11:00 PM PT, Oct. 20) -- Nektar Therapeutics (Nasdaq: NKTR ) today announced that Novartis AG has agreed to acquire from Nektar specific pulmonary delivery assets, technology, and intellectual property for $115 million in cash. "This ag...

Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe

Readies R & D facilities for Ap3ana, CTI's 'personalized medicine' venture SEATTLE, Oct. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ) announced today that Christina A. Waters, Ph.D., M.B.A., most recently President and COO of a Tyr Pharma and formerly Director of S...

Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will ...

MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. announced today that it has licensed its proprietary reverse genetics intellectual property to Novartis to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic and pandemic...

Prix Galien USA Announces 2009 Final Candidates

...ical Agent: AstraZeneca, CRESTOR(R) Celgene, Vidaza(R) novartis Oncology, GLEEVEC(R) novartis Pharmaceuticals, EXELON(R)( )PATCH Pfizer, Zyvox(R) Schering-Pl...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

...the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees. Voltaren(R) Gel is owned and licensed by novartis AG; SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R) for the palliative treatment of advanced prostate cancer, and SUPPRE...

Schering-Plough Reports Financial Results for 2009 Second Quarter

...ned virologic response compared to current standard of care. (Announced April 23) Announced changes to the company's global collaboration with novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease. ...

Novartis in Biological Definition

Monoclonal antibody

...Ortho Biotech . Retrieved 2005-03-10. ^ ZENAPAX (daclizumab) Information page at Roche Pharmaceuticals . Retrieved 2005-03-10. ^ novartis product page for Simulect (basiliximab for injection) . Retrieved 2005-03-09. ...

Systems biology

...publications in systems biology Bibliography Gregory Bock and Jamie A. Goode (eds), (2002) "In Silico" Simulation of Biological Processes , novartis Foundation Symposium 247, John Wiley & Sons Ltd,, ISBN 0-470-84480-9 Hiroaki Kitano (editor), (2001) Foundations of Systems Biology , MIT Pre...